| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,789,000 | - | ||
| General, administrative and other | 2,249,000 | - | ||
| Total operating expenses | 5,038,000 | - | ||
| Loss from operations | -5,038,000 | - | ||
| Change in fair value of sepa put option liability | 33,000 | - | ||
| Change in fair value of convertible debt | -846,000 | - | ||
| Other income/(expense) | 0 | 0 | ||
| Interest income | 73,000 | - | ||
| Interest expense | 0 | 0 | ||
| Change in fair value of warrant liability | - | 0 | ||
| Commitment fee expenses | - | 0 | ||
| Total other income/(expense) | -740,000 | - | ||
| Net loss | -5,778,000 | -4,658,000 | ||
| Net income (loss) attributable to common stockholders | - | -4,658,000 | ||
| Net loss per common share attributable to common stockholders, basic | -0.13 | -0.12 | ||
| Net loss per share, diluted | -0.13 | -0.12 | ||
| Weighted-average shares outstanding, basic | 43,072,542 | 38,635,264 | ||
| Weighted-average shares outstanding, diluted | 43,072,542 | 38,635,264 | ||
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)